cis-[PtCl2(3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)2] | 1028684-44-7

• 英文名称: cis-[PtCl2(3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)2]
• 英文别名: cis-dichlorobis(3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)platinum(II)；cis-[PtCl₂(3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)₂]；cis-PtCl₂(3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)₂；cis-[PtCl₂(DAPTA)₂]；cis-PtCl₂(DAPTA)₂
• CAS: 1028684-44-7
• 化学式: C₁₈H₃₂Cl₂N₆O₄P₂Pt
• 分子量: 724.423
• InChiKey: HJPPHIARKKCEGP-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  None
• 重原子数：
  None
• 可旋转键数：
  None
• 环数：
  None
• sp3杂化的碳原子比例：
  None
• 拓扑面积：
  None
• 氢给体数：
  None
• 氢受体数：
  None

反应信息

• 作为反应物：
  描述：

  3-乙炔基吡啶 、 cis-[PtCl2(3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)2] 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 0.48h， 以80%的产率得到cis-[Pt{C₂(m-py)}₂(DAPTA)₂]
  参考文献：
  名称：

  Bis(alkynyl) PTA and DAPTA complexes of Pt(II) and Pd(II)

  摘要：

  Platinum(II) and palladium(II) complexes containing two substituted alkynyl groups and two PTA or DAFTA ligands (PTA = 1,3,5-triaza-7-phosphaadamantane; DAPTA = 3,7-diacety1-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane) with the general formulas cis- or trans-M(PR3)(2)(C equivalent to CR)(2) (PR3 = PTA or DAPTA) were prepared by a ligand displacement reaction starting from M(C equivalent to CR)(2)(COD) precursors or by a metathesis reaction utilizing MCl2(PR3)(2) precursors in yields ranging from 68% to 89%. The substituted alkynyl groups employed were (Ca equivalent to CR) (R = p-tolyl, o-pyridyl, m-pyridyl, m-C6H4NH2, and CH2Ph). The new complexes were characterized by multinuclear NMR and IR spectroscopy, MS and elemental analysis. The molecular structures of the complexes, cis-Pt(PTA)(2)(C equivalent to C-p-to1)(2)(cis-1), trans-Pt(PTA)(2) (C equivalent to C-o-py)(2) (trans-3), and trans-Pd(PTA)(2)(C equivalent to C-o-py)(2) (trans-4) were confirmed by single crystal X-ray crystallography. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.poly.2014.11.003
• 作为产物：
  描述：

  platinum(II) chloride 、 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane 以 二氯甲烷 为溶剂， 生成 cis-[PtCl2(3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)2]
  参考文献：
  名称：

  trans-Thionate Derivatives of Pt(II) and Pd(II) with Water-Soluble Phosphane PTA and DAPTA Ligands: Antiproliferative Activity against Human Ovarian Cancer Cell Lines

  摘要：

  A series of PTA and DAPTA platinum(II) and palladium(II) thionate complexes of the type trans-[M(SN)(2)P-2] were prepared from the reaction of cis-[MCl2P2] [M = Pt, Pd; P = PTA (1,3,5-triaza-7-phosphaadamantane), DAPTA (3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)] with the in situ generated sodium salts of the heterocyclic thiones S-m-methylpyrimidine-2-thione, S-4,6-dimethylpyrimidine-2-thione, S-4,6-dihydroxypyrimidine-2-thione, benzothiazole-2-thione, benzoxazole-2-thione, S-1,3,4,-thiadiazole-2-thione, S-4,5-H-thiazolan-2-thione, and S-primidine-4(1H)-one-2-thione. The X-ray structures of six of the compounds confirm the trans disposition and, only in the case of [Pd2Cl2(S-pyrimidine-4(1H)-one-2-thionate)(2)(PTA)(2)], a dinuclear structure with a Pd-Pd distance of 3.0265(14)angstrom was observed. In vitro cytotoxicities against human ovarian cancer cell lines A2780 and A2780cisR were evaluated for ten complexes showing a high inhibition of cellular growth with a comparable inhibitory potency (IC50) against A2780 cells to that of cisplatin. Notably, the compounds also show significant (up to 7-fold higher) activity in cisplatin-resistant A2780cisR cell lines.

  DOI：

  10.1021/ic4006746

文献信息

• Synthesis and characterization of Pt(II) and Pd(II) PTA and DAPTA complexes
  作者：Janet Braddock-Wilking、Sitaram Acharya、Nigam P. Rath

  DOI：10.1016/j.poly.2014.04.040

  日期：2014.9

  cis- and trans-Pt(II) and Pd(II) complexes containing two PTA or DAPTA ligands (PTA = 1,3,5-triaza-7-phosphaadamantane; DAPTA = 3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane) with the general formulas, [PtR2(PTA)2], [M(Me)X(PTA)2], [Pt(Et)X(PTA)2], [MR2(DAPTA)2], [MX2(DAPTA)2], and [M(Me)X(DAPTA)2] (where M = Pt or Pd; R = Me, Et, CCR (R = Ph, SiMe3); X = Cl, Br, I) were prepared by ligand

  一系列含有四个PTA或DAPTA配体的四坐标，空气稳定性和水溶性的顺式和反式PT（II）和Pd（II）配合物（PTA = 1,3,5-triaza-7-phosphaadamanTAne; DAPTA = 3通式[PTR 2（PTA）2 ]，[M（Me）X（PTA）2 ]，[ PT（Et）X（PTA）2 ]，[MR 2（DAPTA）2 ]，[MX 2（DAPTA）2 ]和[M（Me）X（DAPTA）2 ]（其中M = PT或Pd； R ＝ Me，Et，CCR（R ＝ Ph，SiMe 3； X ＝ Cl，Br，I）是从[M（R）2（COD）]，[M（R）（X）（COD）]或使用[MCl 2（PR 3）2 ]前体的前体或复分解反应，产率高（63％–90％）。配合物通过多核NMR，IR，MS和元素分析实验进行表征，某些情况下通过X射线晶体学研究进行表征。络合物，顺式- [PTME 2（PTA）2
• Synthesis, Characterization, and in Vitro Cytotoxicity of Some Gold(I) and Trans Platinum(II) Thionate Complexes Containing Water-Soluble PTA and DAPTA Ligands. X-ray Crystal Structures of [Au(SC₄H₃N₂)(PTA)], <i>trans</i>-[Pt(SC₄H₃N₂)₂(PTA)₂], <i>trans</i>-[Pt(SC₅H₄N)₂(PTA)₂], and <i>trans</i>-[Pt(SC₅H₄N)₂(DAPTA)₂]
  作者：Susana Miranda、Elena Vergara、Fabian Mohr、Dick de Vos、Elena Cerrada、Aránzazu Mendía、Mariano Laguna

  DOI：10.1021/ic7021903

  日期：2008.7.7

  highly water soluble gold(I) complexes [Au(SR)(P)] [P = PTA and SR = SPy ( 1), SPyrim ( 2); P = DAPTA and SR = SPy ( 3), SPyrim ( 4)] showed low cytotoxicity, while the platinum(II) complexes trans-[Pt(SR) 2(P) 2] [P = PTA and SR = SPyrim ( 5), SPy ( 6); P = DAPTA and SR = SPyrim ( 7), SPy ( 8)] demonstrated potent cytotoxicity for ovarian, colon, renal, and melanoma cancer cell lines on the basis of

  [Au（SR）（P）]和反式-[Pt（SR）2（P）2] [SR = 2-硫代吡啶（SPy），2 -硫代嘧啶（SPyrim）; 制备并表征P ＝ 1,3,5-三氮杂-7-磷酸金刚烷（PTA），3,7-二乙酰基-1,3,7-三氮杂-5-磷酸双环[3.3.1]壬烷（DAPTA）]，并对其进行表征。评估了它们对一组七种人类癌细胞系的体外细胞毒性。高水溶性金（I）配合物[Au（SR）（P）] [P = PTA，SR = SPy（1），SPyrim（2）；P = DAPTA和SR = SPy（3），SPyrim（4）]显示出低细胞毒性，而铂（II）配合物反式-[Pt（SR）2（P）2] [P = PTA和SR = SPyrim（5 ），SPy（6）; P = DAPTA，SR = SPyrim（7），SPy（8）]对卵巢，结肠，肾，与某些已确立的细胞毒性药物的ID 50值进行比较的基础上，确定黑素瘤